Cargando…

Accelerated Infliximab Infusion: Safety, Factors Predicting Adverse Events, Patients’ Satisfaction and Cost Analysis. A Cohort Study in IBD Patients

BACKGROUND: Standard Infliximab infusion consists of a 2-hour intravenous administration. Recently, Infliximab shortened infusion has been included in the Infliximab label as possible maintenance regimen for patients tolerating Infliximab induction therapy. AIM: To verify if accelerated 1-hour Infli...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mazzuoli, S., Tricarico, D., Demma, F., Furneri, G., Guglielmi, F. W.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5112916/ https://www.ncbi.nlm.nih.gov/pubmed/27851772 http://dx.doi.org/10.1371/journal.pone.0166443

Ejemplares similares

Biosimilar infliximab use in paediatric IBD
por: Richmond, Lisa, et al.
Publicado: (2018)

Infliximab in young paediatric IBD patients: it is all about the dosing
por: Jongsma, Maria M. E., et al.
Publicado: (2020)

Infliximab and biosimilar infliximab in psoriasis: efficacy, loss of efficacy, and adverse events
por: Subedi, Smriti, et al.
Publicado: (2019)

Accelerated Infliximab Infusion Safety and Tolerability Is Non-inferior to Standard Infusion Protocol in Inflammatory Bowel Disease Patients: A Randomized Controlled Study
por: Abushamma, Suha, et al.
Publicado: (2023)

Safety of Accelerated Infliximab Infusions in Children With Inflammatory Bowel Disease: A Retrospective Cohort Study
por: Jagt, Jasmijn Z., et al.
Publicado: (2023)

Infusion reaction to infliximab biosimilar after transitioning from infliximab
por: Kashlan, Reem, et al.
Publicado: (2020)

Seizure During Infliximab Infusion in a Child With Crohn’s Disease: An Illustration of a Neurologic Adverse Event Associated With Drug Antibodies
por: Joseph, Shelly, et al.
Publicado: (2021)

Antibody responses to SARS-CoV-2 infection are attenuated in infliximab-treated patients with IBD
por: Ray, Katrina
Publicado: (2021)

Predictors of infusion reactions during infliximab treatment in patients with arthritis
por: Kapetanovic, Meliha C, et al.
Publicado: (2006)

Knowledge of Fecal Calprotectin and Infliximab Trough Levels Alters Clinical Decision-making for IBD Outpatients on Maintenance Infliximab Therapy
por: Huang, Vivian W., et al.
Publicado: (2015)

Infliximab in patients with psoriasis and other inflammatory diseases: evaluation of adverse events in the treatment of 168 patients
por: Antonio, João Roberto, et al.
Publicado: (2016)

A quality improvement project reduces time spent at an inflammatory bowel disease infusion center with accelerated infliximab infusion protocol
por: Ong, Wan Chee, et al.
Publicado: (2022)

Infliximab-Related Infusion Reactions: Systematic Review
por: Lichtenstein, Lev, et al.
Publicado: (2015)

Infliximab for Treatment of Immune Adverse Events and Its Impact on Tumor Response
por: Parvathareddy, Vishnupriyadevi, et al.
Publicado: (2023)

Rapid infusion of infliximab biosimilars and the incidence and severity of infusion‐related reactions in patients with inflammatory bowel disease
por: Rusch, Caroline, et al.
Publicado: (2022)

Nutritional Regimes Enriched with Antioxidants as an Efficient Adjuvant for IBD Patients under Infliximab Administration, a Pilot Study
por: Liso, Marina, et al.
Publicado: (2022)

90K/Mac-2 BP Is a New Predictive Biomarker of Response to Infliximab Therapy in IBD Patients
por: Pesole, Pasqua Letizia, et al.
Publicado: (2023)

Efficacy and safety of Infliximab for steroid-resistant immune-related adverse events: A retrospective study
por: Kadokawa, Yukio, et al.
Publicado: (2021)

Risk of Adverse Pregnancy Outcomes for Women with IBD in an Expert IBD Antenatal Clinic
por: Lever, Gillian, et al.
Publicado: (2022)

Is there a correlation between infliximab trough levels and the development of adverse events in patients with inflammatory bowel disease?
por: Theodoraki, Eirini, et al.
Publicado: (2021)

Skin microbiota signature distinguishes IBD patients and reflects skin adverse events during anti-TNF therapy
por: Reiss, Zuzana, et al.
Publicado: (2023)

Immediate-type infliximab infusion reaction presenting as purpura
por: Soong, Laura, et al.
Publicado: (2018)

Mucosal Healing Did Not Predict Sustained Clinical Remission in Patients with IBD after Discontinuation of One-Year Infliximab Therapy
por: Dai, Cong, et al.
Publicado: (2014)

Efficacy of Switching from Infliximab to Subcutaneous Golimumab in Patients with Rheumatoid Arthritis to Control Disease Activity or Adverse Events
por: Wakabayashi, Hiroki, et al.
Publicado: (2016)

IBD Patients Could Be Silent Carriers for Novel Coronavirus and Less Prone to its Severe Adverse Events: True or False?
por: Ghavami, Shaghayegh Baradaran, et al.
Publicado: (2020)

Detecting early safety signals of infliximab using machine learning algorithms in the Korea adverse event reporting system
por: Lee, Jeong-Eun, et al.
Publicado: (2022)

Autoimmune hemolytic anemia associated with infliximab infusion in ulcerative colitis
por: Mir, Fazia A., et al.
Publicado: (2018)

Incidence and Management of Infusion Reactions to Infliximab in an Alternate Care Setting
por: Checkley, L. Allyson, et al.
Publicado: (2018)

Effect of Standardized Infliximab Dose Rounding on an Outpatient Infusion Center
por: Park, Jiyeon Joy, et al.
Publicado: (2018)

Su1485: COVID-19 VACCINE-INDUCED ANTIBODY RESPONSES ARE IMPAIRED IN IBD PATIENTS TREATED WITH INFLIXIMAB, USTEKINUMAB OR TOFACITINIB, BUT NOT THIOPURINES OR VEDOLIZUMAB
por: Alexander, James L., et al.
Publicado: (2022)

Real World Outcomes and Hepatotoxicity of Infliximab in the Treatment of Steroid-Refractory Immune-Related Adverse Events
por: Araujo, Daniel V., et al.
Publicado: (2021)

Assessment of costs associated with adverse events in patients with cancer
por: Wong, William, et al.
Publicado: (2018)

Costs associated with adverse events among acute patients
por: Kjellberg, Jakob, et al.
Publicado: (2017)

Analysis of Adverse Events and Intravenous Iron Infusion Formulations in Adults With and Without Prior Infusion Reactions
por: Arastu, Asad H., et al.
Publicado: (2022)

Linear IgA dermatosis after infliximab infusion for ulcerative colitis
por: Bryant, Kelli D., et al.
Publicado: (2016)

Implementation and Evaluation of a Standard Operating Procedure for Pediatric Infliximab Infusions
por: Kelly, Maureen M., et al.
Publicado: (2019)

Rapid point-of-care anti-infliximab antibodies detection in clinical practice: comparison with ELISA and potential for improving therapeutic drug monitoring in IBD patients
por: Facchin, Sonia, et al.
Publicado: (2021)

Patient preferences and satisfaction in a multispecialty infusion center
por: Ostrov, Barbara E, et al.
Publicado: (2014)

Recurrent acute coronary syndrome after infliximab infusion in a patient with rheumatoid arthritis: Case report
por: Rebolledo Del Toro, Martin, et al.
Publicado: (2023)

A Drug Safety Rating System Based on Postmarketing Costs Associated with Adverse Events and Patient Outcomes
por: Hoffman, Keith B., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_mu8pl3ujknl6ja00toeredu8oh